Afatinib and Dacomitinib are second-line EGFR TKIs that bind to EGFR permanently and show beneficial effects in cancer therapy, but there have been toxicity concerns due to elevated wild-type EGFR off-target binding [7]. The gene discussed is EGFR; the disease is cancer.